Clinical
pathological study of treatment of chronic hepatitis with hyperbaric
oxygenation
“Hepatitis C”
Liu W, Zhao W, Lu
X, Zheng X, Luo C.Department of
Gastroenterology, The Affiliated Nanjing Second Hospital of the Medical College
of Nanjing Southeast University, Nanjing 210003, China
OBJECTIVE: To detect the feasibility and theoretic basis for treatment with
hyperbaric oxygenation (HBOT) in chronic hepatitis and to compare the changes
in hepatic function, immunity, pathologic morphology, ultra structure and HBV
in hepatic tissues before and after treatment. METHODS: Sixty cases of chronic
hepatitis were randomly selected and divided into two groups: the experiment (n
= 30) and control groups (n = 30). Patients in the experimental group were
treated with HBOT for 6 courses. Patients in the control group were treated for
60 days with the usual drugs used in the clinic. The function and bloodstream
graph of liver were examined and liver biopsies were made before and after
treatments. Routine paraffin sections were stained with HE and observed under
the light microscope. Ultra thin slides from paraformaldehyde and
glutaraldehyde fixed liver tissue were stained with lead citrate and observed
with the transmission electric microscope. HBsAg and HBcAg in liver of the
experimental group were detected with ABC immunohistochemistry method before
and after treatment.
RESULTS: For the
experimental group, ALT, SB, gamma-GT, AKP, IgG, and IgM in blood and the
degeneration and necrosis of hepatocytes were remarkably decreased (P < 0.05
), the mean contractive wave of bloodstream in liver and the bloodstream in
right ramus of janitrix were remarkably increased (P < 0.05), and the
swelling of mitochondria, increase of lysosomes, generation of Kupffer cells,
infiltration of lymphocytes in portal area and capillary generation were all
remarkably all eviated (P < 0.05) after treatment with HBOT. There were
significant differences between the experimental and control groups after
treatment with different methods (P < 0.05). For patients in the
experimental group, the fibrosis and fat-storing cells in the liver were not
reduced (P > 0.05), and the expression of HBsAg and HBcAg in liver was not
weakened (P < 0.05) after treatment.
CONCLUSIONS: Treatment with HBOT for chronic hepatitis was
effective and recommendable, but it could not reverse liver fibrosis. However,
it might be able to delay or prevent the liver from fibrosis, so it might be
more effective at the early and middle stages of chronic hepatitis. HBOT could
not inhibit the HB virus. So we consider that treatment with HBOT should be
simultaneous with anti HBV therapy.
Chin Med J (Engl). 2002 Aug;115(8):1153-7.